Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?

Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?

Background: Afatinib can be started at a dose lower than the recommended starting dose of 40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), however treatment outcomes in real-world clinical practice remains unclear. Methods: This retros...

Full description

Bibliographic Details
Published in:Translational Lung Cancer Research
Main Author: Poh M.E.; Chai C.S.; Liam C.K.; Ho G.F.; Pang Y.K.; Hasbullah H.H.; Tho L.M.; Nor I.M.; Ho K.F.; Thiagarajan M.; Samsudin A.; Omar A.; Ong C.K.; Soon S.Y.; Tan S.N.; How S.H.
Format: Article
Language:English
Published: AME Publishing Company 2024
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85187361126&doi=10.21037%2ftlcr-23-691&partnerID=40&md5=0a25ce0a188c1c22ca551132d79b4f90

Internet

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85187361126&doi=10.21037%2ftlcr-23-691&partnerID=40&md5=0a25ce0a188c1c22ca551132d79b4f90

Similar Items